Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 10/2000

01-11-2000 | ORIGINAL ARTICLE

Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival

Authors: Michele Orditura, Ciro Romano, Ferdinando De Vita, Gennaro Galizia, Eva Lieto, Stefania Infusino, Giuseppe De Cataldis, Giuseppe Catalano

Published in: Cancer Immunology, Immunotherapy | Issue 10/2000

Login to get access
Metadata
Title
Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival
Authors
Michele Orditura
Ciro Romano
Ferdinando De Vita
Gennaro Galizia
Eva Lieto
Stefania Infusino
Giuseppe De Cataldis
Giuseppe Catalano
Publication date
01-11-2000
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 10/2000
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620000150

Other articles of this Issue 10/2000

Cancer Immunology, Immunotherapy 10/2000 Go to the issue

ORIGINAL ARTICLE

Regulation of CD40L expression on natural killer cells by interleukin-12 and interferon γ: its role in the elicitation of an effective antitumor immune response

ORIGINAL ARTICLE

The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines

ORIGINAL ARTICLE

Targeting of cancer cells with monoclonal antibodies specific for C3b(i)

ORIGINAL ARTICLE

Generation and functional characterisation of dendritic cells from patients with pancreatic carcinoma with special regard to clinical applicability

ORIGINAL ARTICLE

Granulocyte/macrophage-colony-stimulating factor augments lymphokine-activated killer activity from lymphocytes via macrophages in lung cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits